Cargando…

Dalfampridine Prior Authorization Program: A Cohort Study

BACKGROUND: Dalfampridine (Ampyra) is indicated to improve walking in patients with multiple sclerosis (MS) and was found to be effective in 35%-43% of individuals with MS in clinical trials. Dalfampridine may increase seizure risk, particularly in patients with renal impairment. A U.S. managed care...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gleason, Patrick P., Phillips, Jill, Fenrick, Beckie A., Delgado-Riley, Ana, Starner, Catherine I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437843/ https://www.ncbi.nlm.nih.gov/pubmed/23383704 http://dx.doi.org/10.18553/jmcp.2013.19.1.18

Ejemplares similares

Rosiglitazone Prior Authorization Safety Policy: A Cohort Study
por: Starner, Catherine I., et al.
Publicado: (2012)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

Cholinesterase Inhibitor Utilization Patterns: Just Because It Can Be Counted Does Not Mean It Counts
por: Starner, Catherine I., et al.
Publicado: (2008)

Association of a Controlled Substance Scoring Algorithm with Health Care Costs and Hospitalizations: A Cohort Study
por: Starner, Catherine I., et al.
Publicado: (2016)

Drug super spender tsunami: An integrated medical and pharmacy benefits assessment
por: Starner, Catherine I, et al.
Publicado: (2022)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

Objective and subjective measures of dalfampridine efficacy in clinical practice
por: Klineova, Sylvia, et al.
Publicado: (2018)

Generic Drug Discount Programs: Are Prescriptions Being Submitted for Pharmacy Benefit Adjudication?
por: Tungol, Alexandra, et al.
Publicado: (2012)

Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2
por: Malamud, Emily, et al.
Publicado: (2022)

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program
por: Crayton, Heidi, et al.
Publicado: (2014)

Pharmacy Students' Views of Managed Care Pharmacy and PBMs: Should There Be More Exposure to Managed Care in the Pharmacy Curriculum?
por: Pittenger, Amy L., et al.
Publicado: (2010)

Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis
por: Marshall, Landon Z, et al.
Publicado: (2023)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis
por: Schwartz, Kateryna, et al.
Publicado: (2017)

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis
por: Shi, Jianzhen, et al.
Publicado: (2019)

Rosiglitazone and Pioglitazone Utilization from January 2007 Through May 2008 Associated With Five Risk-Warning Events
por: Starner, Catherine I., et al.
Publicado: (2008)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS
por: Solaro, C., et al.
Publicado: (2015)

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Association of Prescription Abandonment with Cost Share for High-Cost Specialty Pharmacy Medications
por: Gleason, Patrick, et al.
Publicado: (2009)

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Impact of formulary restriction with prior authorization by an antimicrobial stewardship program
por: Reed, Erica E., et al.
Publicado: (2013)

Identification of metabolites of dalfampridine (4-aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways
por: Caggiano, Anthony, et al.
Publicado: (2013)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
por: Jara, Michele, et al.
Publicado: (2014)

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
por: Sadeqi, Yasaman, et al.
Publicado: (2022)

A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke
por: Page, Stephen J., et al.
Publicado: (2020)

Benefits of Prior Authorizations
por: Forrester, Caroline
Publicado: (2020)

Perceptions of Saskatchewan Community Pharmacists Regarding a Prior-Authorization Program
por: Perepelkin, Jason, et al.
Publicado: (2007)

Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
por: Zaman, Rameez, et al.
Publicado: (2022)

Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions
por: Gleason, Patrick P., et al.
Publicado: (2013)

Introduction to the Galois correspondence
por: Fenrick, Maureen H
Publicado: (1998)

Introduction to the Galois correspondence
por: Fenrick, Maureen H
Publicado: (1992)

Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study
por: Samara, Emil, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ckedplqnvnriiuf65dstl6vgel